2016-07-15T20:47:15-05:00 2014-08-31 KPMG LLP 550 S Hope St Suite 1500 Los Angeles CA 90071 990 2013-09-01 453682796 California Institute for Biomedical research % AMANDA ARELLANO CALI 8582421029 11119 N TORREY PINES RD LA JOLLA CA 92037 SABRINA JOHNSON TREASURER 8582421029 2016-07-15 true Chad Franks P01071312 8582421029 2016-07-13 2013 2016-12-15 16:53:06Z X PETER G SCHULTZ PhD 11119 NTORREY PINES RD 100 LA JOLLA CA 92037 18363092 false X www.calibr.org X 2011 CA The California Institute for Biomedical Research (Calibr) accelerates the translation of basic biomedical research to new medicines for unmet medical needs. 5 4 93 0 0 21590 107277 11888901 18152565 2153 102365 0 885 11912644 18363092 0 0 0 0 4410824 6180146 0 0 0 7819331 10750278 12230155 16930424 -317511 1432668 8232698 13391411 4755166 8481211 3477532 4910200 X OUR MISSION IS TO BUILD A UNIQUE INSTITUTE THAT BRIDGES BASIC RESEARCH AND DRUG DISCOVERY, AND THAT ATTRACTS THE BEST AND BRIGHTEST SCIENTISTS, PHYSICIANS AND STUDENTS TO WORK TOGETHER SYNERGISTICALLY TO FIND CURSES FOR NEGLECTED HUMAN DISEASES. THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (CALIBR) IS A BIOMEDICAL RESEARCH ORGANIZATION LOCATED IN SAN DIEGO, CALIFORNIA. CALIBR BRIDGES THE GAP BETWEEN BASIC BIOMEDICAL RESEARCH AND THE CLINICAL APPLICATION OF RESEARCH DISCOVERIES TO HUMAN DISEASE. CALIBR COMMITS SUBSTANTIALLY ALL OF ITS RESOURCES TO BIOMEDICAL RESEARCH ACTIVITIES. CALIBR'S RESEARCH AND WORK WILL CATALYZE THE TRANSLATION OF DISCOVERIES BY SCIENTISTS AT SCRIPPS RESEARCH INSTITUTE, AND OTHER SAN DIEGO RESEARCH INSTITUTES (SUCH AS U.C. SAN DIEGO AND SALK INSTITUTE), AS WELL AS OTHER MAJOR RESEARCH INSTITUTES THROUGHOUT THE WORLD, INTO POTENTIAL NEW THERAPIES FOR MANY LIFE THREATENING AND DEBILITATING DISEASES. THESE DISEASES INCLUDE ORPHAN DISEASES, DEGENERATIVE DISEASES false false 15046821 0 18152565 RESEARCH GRANTS AND CONTRACTS ARE RECEIVED FROM PUBLIC AND PRIVATE INSTITUTIONS AND ARE USED TO CONDUCT BIOMEDICAL RESEARCH. IN THE CURRENT FISCAL YEAR, CALIBR CONDUCTED RESEARCH THROUGH A PRIVATE COLLABORATION AGREEMENT ON AUTOIMMUNE AND INFLAMMATORY DISEASES, CANCER BIOLOGY, CARDIOVASCULAR METABOLIC DISEASES AND NEUROBIOLOGY. IN ADDITION, IT CONDUCTED RESEARCH FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY, JUVENILE DIABETES, and TB DRUG DEVELOPMENT. 0 15046821 true true false false false false false false false true false false false true true true false false false false false false false false false false false false true false false false false false false false true false false false false false false false false false true 21 0 true 93 true false false false false false false false false false false X 5 4 true false false false false false false true true false false true true true true true true false false false CA X AMANDA ARELLANO 8582421029 11119 N TORREY PINES RD SUITE 10 LA JOLLA CA 92037 PETER G SCHULTZ PRESIDENT/BOARD CHAIR 20.0 0.0 X X 0 0 0 MARK EDWARDS BOARD MEMBER 1.0 0.0 X 0 0 0 ISY GOLDWASSER BOARD MEMBER 1.0 0.0 X 0 0 0 RICK LUFTON BOARD MEMBER (THRU 6/19/14) 1.0 0.0 X 0 0 0 PAUL SCHIMMEL BOARD MEMBER 1.0 0.0 X 0 0 0 CHRIS WALSH BOARD MEMBER (FROM 6/19/14) 1.0 0.0 X 0 0 0 MATTHEW TREMBLAY SECRETARY (FROM 8/18/14) 40.0 0.0 X 113500 0 0 AMANDA ARELLANO TREASURER (FROM 8/18/14) 40.0 0.0 X 62952 0 5220 AMIT BHATIA VP/TREAS/SECY (THRU 12/31/13) 40.0 0.0 X 193250 0 10041 ARNAB CHATERJEE DIRECTOR, MEDICINAL CHEMISTRY 40.0 0.0 X 153638 0 0 523340 0 15261 3 false true false 0 107277 107277 MEDICAL RESEARCH 541700 18152565 18152565 18152565 102365 102365 0 0 0 0 0 0 0 0 0 OTHER INCOME 900099 885 885 885 18363092 18152565 103250 0 0 0 0 455557 277618 177939 0 4737979 4179197 558782 0 541702 510823 30879 444908 398890 46018 0 53880 53880 34593 34593 0 0 0 332611 216197 116414 0 776060 356988 419072 399836 351856 47980 0 2034091 1790000 244091 22582 22582 0 5836 5836 0 0 1003566 913245 90321 17929 17929 LAB SUPPLIES 3860672 3860672 0 0 CONTRACT RESEARCH 1100123 1100123 LABORATORY SERVICES 586493 586493 OUTSOURCED RESEARCH 290695 290695 231311 191442 39869 16930424 15046821 1883603 0 0 300 2101437 6490934 397558 853120 0 0 0 0 0 0 0 0 0 0 194321 192909 7755989 1991163 5522720 5764826 0 0 0 0 0 0 16662 89322 0 0 8232698 13391411 645308 895733 0 0 3414950 6698581 0 0 0 0 0 0 0 0 0 0 694908 886897 4755166 8481211 X 3477532 4910200 0 0 0 0 3477532 4910200 8232698 13391411 1432668 X false true X false false X UC San Diego Medical Center San Diego CA Scripps Memorial Hospital La Jolla La Jolla CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 7755989 1991163 5764826 0 5764826 0 DEFERRED RENT 886897 886897 X 19659708 1296616 1296616 18363092 18363092 18227040 1296616 1296616 16930424 16930424 Schedule D, Part X, Line 2 THE INSTITUTE ADOPTED ACCOUNTING GUIDANCE RELATING TO ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES, WHICH IS PRIMARILY CODIFIED IN FINANCIAL ACCOUNTING STANDARDS BOARD (FASB) ACCOUNTING STANDARDS CODIFICATION 740. THE INSTITUTE FILES A FORM 990 (RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX) ANNUALLY. WHEN THESE RETURNS ARE FILED, IT IS HIGHLY CERTAIN THAT SOME POSITIONS TAKEN WOULD BE SUSTAINED UPON EXAMINATION BY THE TAXING AUTHORITIES, WHILE OTHERS ARE SUBJECT TO UNCERTAINTY ABOUT THE MERITS OF THE TAX POSITION TAKEN OR THE AMOUNT OF THE POSITION THAT WOULD ULTIMATELY BE SUSTAINED. EXAMPLES OF TAX POSITIONS COMMON TO THE INSTITUTE INCLUDE SUCH MATTERS AS THE TAX-EXEMPT STATUS OF THE ENTITY AND VARIOUS POSITIONS RELATIVE TO POTENTIAL SOURCES OF UBI. UBI IS REPORTED ON FORM 990-T, AS APPROPRIATE. THE BENEFIT OF TAX POSITION IS RECOGNIZED IN THE FINANCIAL STATEMENTS IN THE PERIOD DURING WHICH, BASED ON ALL AVAILABLE EVIDENCE, MANAGEMENT BELIEVES IT IS MORE LIKELY THAN NOT THAT THE POSITION WILL BE SUSTAINED UPON EXAMINATION, INCLUDING THE RESOLUTION OF APPEALS OR LITIGATION PROCESSES, IF ANY. TAX POSITIONS ARE NOT OFFSET OR AGGREGATED WITH OTHER POSITIONS. TAX POSITIONS THAT MEET THE MORE-LIKELY-THAN-NOT RECOGNITION THRESHOLD ARE MEASURED AS THE LARGEST AMOUNT OF TAX BENEFIT THAT IS MORE THAN 50 PERCENT LIKELY TO BE REALIZED ON SETTLEMENT WITH THE APPLICABLE TAXING AUTHORITY. THE PORTION OF THE BENEFITS ASSOCIATED WITH TAX POSITIONS TAKEN THAT EXCEEDS THE AMOUNT MEASURED AS DESCRIBED ABOVE IS REFLECTED AS A LIABILITY FOR UNRECOGNIZED TAX BENEFITS IN THE ACCOMPANYING STATEMENTS OF FINANCIAL POSITION, ALONG WITH ANY ASSOCIATED INTEREST AND PENALTIES THAT WOULD BE PAYABLE TO THE TAXING AUTHORITIES UPON EXAMINATION. AS OF AUGUST 31, 2014 AND 2013, THE INSTITUTE HAS ADDRESSED UNCERTAINTY IN ITS INCOME TAX POSITION UNDER THE GUIDANCE, AND THERE ARE NO UNRECOGNIZED/DERECOGNIZED TAX BENEFITS REQUIRING AN ACCRUAL. FORMS 990 AND 990-T FILED BY THE INSTITUTE ARE SUBJECT TO EXAMINATION BY THE INTERNAL REVENUE SERVICE UP TO THREE YEARS FROM THE EXTENDED DUE DATE OF EACH RETURN. MANAGEMENT BELIEVES FORMS 990 AND 990-T HAVE BEEN FILED APPROPRIATELY. DATE OF EACH RETURN. MANAGEMENT BELIEVES FORMS 990 AND 990-T HAVE BEEN FILED APPROPRIATELY. true false false false false false false false false AMIT BHATIA VP/TREAS/SECY (THRU 12/31/13) 145750 0 0 0 47500 0 0 0 10041 0 203291 0 0 0 ARNAB CHATERJEE DIRECTOR, MEDICINAL CHEMISTRY 153638 0 0 0 0 0 0 0 0 153638 0 0 0 SEVERANCE PAYMENTS SCHEDULE J, LINE 4a A SEVERANCE PAYMENT IN THE AMOUNT OF $47,500 WAS PROVIDED TO AMIT BHATIA, VP OF FINANCE & ADMINISTRATION, UPON SEPARATION FROM CALIBR. Peter Schultz President 2376645 see part V below false Description of transaction Schedule L, Part IV, Column (d) The CALIBR business transaction with Ambrx provides funding to support the research and development work at CALIBR. The Interested person listed above is also a board member of AMBRX, Inc. The terms of the transaction and nature of the funding are favorable to CALIBR and the pursuit of CALIBR's mission. Specifically, the transaction does not confer any rights to Ambrx other than the opportunity to review the research findings to determine if there is interest in providing additional funding or licensing the technology from CALIBR in exchange for financial consideration to CALIBR. The interested person has been recused from all decision-making making related to the transaction, including but not limited to the decision to enter into the agreement, renew the agreement, terminate the agreement, and any other contemplated consideration. Independent board members discuss all interested person transactions, the alternatives, and evaluate what is best for the organization. Meeting minutes reflect the discussions and decision, including who voted and who was recused from discussion and voting. BUSINESS RELATIONSHIP PART VI, SECTION A, LINE 2 President and board member Peter Schultz serves on a number of other corporate boards with board member Isy Goldwasser. FORM 990 REVIEW PROCESS PART VI, SECTION B, LINE 11B INFORMATION USED TO PREPARE THE FORM 990 WAS COMPILED BY CALIBR'S PERSONNEL. THE RETURN WAS PREPARED WITH THE ASSISTANCE OF ITS PUBLIC ACCOUNTING FIRM. THE FORM 990 WAS REVIEWED BY CALIBR'S AUDIT COMMITTEE, WHICH HAS AUTHORITY AND OVERSIGHT OF CALIBR'S AUDIT AND TAX PREPARATION. A COMPLETE COPY OF THE FORM 990 WAS PROVIDED TO THE FULL BOARD AFTER REVIEW BY THE AUDIT COMMITTEE AND PRIOR TO FILING WITH THE IRS. CONFLICT OF INTEREST POLICY PART VI, SECTION B, LINE 12C On an annual basis, CALIBR distributes conflict of interest questionnaires which the board members, officers, and key employees complete and return. The president and VP of finance and operations review the returned forms for compliance. If a conflict is discovered it is escalated to the appropriate party within CALIBR and the person recuses himself or herself from the governing body's deliberations and decisions in the transaction, and the meeting minutes reflect that the party in question recused themselves. In the event a conflict arises the independent board members discuss the transaction, the alternatives, and evaluate what is best for the organization. Meeting minutes reflect the discussions and decision, including who voted and who was recused from discussion and voting. Board members are required to bring forth any new conflicts of interest as they arise. OFFICER COMPENSATION FORM 990, LINE 15A & 15B In accordance with the governing principles of the Institute's Director Compensation Policy, the maximum total cash compensation is to be determined by publicly available data as reviewed by non-employee, disinterested members of the Board. The Board ensures that compensation of the Institute Director shall be reviewed no less than once in three years by disinterested members of the Board. Calibr's President is eligible for a base salary for performance of services in any given one year period and shall automatically be due the Board's predetermined and contemporaneously approved fair and reasonable base salary, subject to an Executive cap of $1.05 M per year. Additionally, the President is eligible to receive bonus incentive pay separate from compensation payments in amounts determined by the Board at its sole reasonable discretion, provided that such bonus shall not cause the total compensation of Executive to exceed the Executive cap. At Executive's sole discretion, Executive may waive the right to receive all or part of the payments due before receipt, provided that the Executive gives written notice to Institute of the amount of payment(s) waived. It is expressly understood by Calibr and Executive that waiver of payment(s) shall in no way alter or influence Institute's future payment obligations to Executive or the determination or implementation of the Executive Cap. The president has waived any other forms of compensation including bonuses and non-monetary benefits and prerequisites for the fiscal year ending 08/31/2014. Other officer salaries are determined by CALIBR'S President based on comparable salaries for individuals having similar roles and responsibilities at similar non-profits and biotech companies. PUBLIC DISCLOSURE OF GOVERNING DOCUMENTS PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. Amended Return Note THIS TAX RETURN HAS BEEN AMENDED AFTER THE ORGANIZATION'S FINANCIAL STATEMENTS WERE AUDITED BY AN INDEPENDENT ACCOUNTANT. IN ADDITION, THE ORGANIZATION RECEIVED CORRESPONDENCE FROM THE IRS REGARDING A CHANGE TO ITS PUBLIC CHARITY STATUS TO A MEDICAL RESEARCH ORGANIZATION UNDER 170(B)(1)(A)(III). CHANGES HAVE BEEN MADE TO THE STATEMENTS OF REVENUE, EXPENSE, THE BALANCE SHEET, SCHEDULE A, SCHEDULE D, AND SCHEDULE L AS FOLLOWS: -PART 1, LINES 9, 10, 12, 15, 17, 18, 19, 20, 21, 22 -PART III, LINE 4A -PART VII, LINES 1 TO 9 -PART VIII, LINE 2A -PART IX, LINES 7, 11A, 11C, 11G, 12, 13, 14, 16, 17, 19, 22, 23, 24B, 24C, 24D, 24E -PART X, LINES 1, 3, 9, 10, 16, 17, 19, 25, 26, 27, 33, 34 -PART XII, LINES 2B, 2C -SCHEDULE A, PART I, LINE 4, 7, AND PART II -SCHEUDLE D, PART VI, LINE 1D -SCHEDULE D, PART X, LINES 1, 2 AND PART XIII -SCHEDULE D, PART XI, AND PART XII, LINES 1, 2, 3, 5 -SCHEDULE L, PART IV, LINES 1, 2 AND PART V -SCHEDULE L, PART IV, LINES 1, 2 AND PART V